Simplicardiac

Cover Block

Open sources

Company Name	Simplicardiac
Tagline	Developing arterial-access-site management devices for interventional cardiology, focusing on post-catheterization care.
Headquarters	Warsaw, Poland
Founded	2013
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed

Note: Total disclosed funding amount is not publicly available.

Links

Open sources

• Website: https://simplicardiac.com/
• LinkedIn: https://www.linkedin.com/company/simplicardiac-sa

What an Investor Needs First

Open sources

Simplicardiac is a Polish medtech company developing automated arterial-access-site management devices for interventional cardiology, a niche with high clinical stakes and persistent procedural inefficiencies [simplicardiac.com]. Founded in 2013, the company has progressed from a government-backed R&D loan to securing investor financing for a commercial push, aiming to address post-catheterization care with its principal product, the SimpliRadial compression band [Biotechnologia.pl, May 2023]. The device, which has international patent protection pending, is designed to provide real-time monitoring and reduce nursing workload, positioning it as a potential tool for improving safety and operational flow in cath labs [simplicardiac.com].

Co-founders Andrzej Białkowski-Miler, a medtech entrepreneur with over 16 years in technology transfer, and Mariusz Kruk, MD, PhD, a professor of cardiology and the device's inventor, provide a blend of commercial and clinical expertise [LinkedIn]. The company's business model targets hospital procurement, though specific revenue figures or commercial deployments are not yet public. Over the next 12-18 months, key milestones will include the outcome of its patent applications, the results of its ongoing recruitment for regulatory and engineering roles, and any announced commercial partnerships or pilot deployments following its presentation at the TCT Innovation conference in late 2024 [simplicardiac.com].

Partially corroborated -- Core company description and product claims are confirmed by primary sources; financing and team details are partially corroborated by secondary press.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed

Inside the Company

Open sources Simplicardiac, a Polish medical device company founded in 2013, has spent the last decade developing a single, specific solution to a well-defined clinical problem: managing the arterial puncture site after cardiac catheterization [simplicardiac.com]. The company's headquarters and primary operations are in Warsaw, Poland, a location that has shaped its funding and development path through a mix of government grants and private investment [simplicardiac.com].

Key milestones follow a logical progression from concept to market preparation. The company's foundational work centered on developing and patenting its core technology, an automated compression band for transradial procedures [simplicardiac.com]. In 2020, it secured a PLN 1.2 million (approximately €265,000) loan from Poland's National Centre for Research and Development (NCBR) to support its research [Onet, May 2020]. By May 2023, the company had reportedly obtained investor financing to repay that loan and fund a commercial-market push for its product [Biotechnologia.pl, May 2023]. Its most recent public milestone was a presentation of its "Automated Arterial Access Site Management" system at the TCT Innovation 1 conference in Washington, D.C., in October 2024, signaling its intent to engage with the global interventional cardiology community [simplicardiac.com].

Verified against public records -- Core company details and historical milestones confirmed by company website and multiple Polish press reports.

Under the Hood

Reported and inferred

Simplicardiac’s entire commercial proposition rests on a single, hardware-focused product concept: an automated compression band for managing arterial access sites after transradial cardiac catheterization. The company’s public materials describe the device, branded SimpliRadial, as a “globally unique Radial Artery Compression Device” designed to provide real-time monitoring, reduce nursing workload, and support safer procedural outcomes by automating what is typically a manual, time-intensive post-procedure task [simplicardiac.com/technology/, 2026]. The core intellectual property is a patent-pending “Medical Device for Blood Vessel Compression,” for which the company is pursuing international protection across multiple jurisdictions, supported by a European Funds co-financed project [simplicardiac.com].

The technology’s intended clinical workflow is clear from company descriptions. It targets the post-cath-lab environment, aiming to replace manual compression and observation with a system that applies consistent pressure and monitors the puncture site. This addresses a specific pain point in interventional cardiology, where the radial artery approach is increasingly favored but requires careful hemostasis to prevent complications. The device’s presentation at the TCT Innovation 1 session on the “Cath Lab of the Future” in October 2024 positions it within a broader trend toward automation and data integration in procedural suites [simplicardiac.com/posts/post03/].

Current hiring provides the clearest signal of the technical stack and development priorities. The open role for a Regulatory Affairs Specialist explicitly mentions acting as the Person Responsible for Regulatory Compliance (PRRC), indicating a critical phase of preparing for CE marking and other medical device approvals [simplicardiac.com]. Simultaneously, the search for a DevOps Engineer/Architect (inferred from job postings) suggests the product includes a software component, likely for device data management, connectivity, or backend services, moving it beyond a purely mechanical solution.

Partially corroborated -- Product claims are sourced from the company website and a 2024 conference presentation. Technical stack details are inferred from active job postings, not from shipped product specifications.

Market Research

Open sources The market for arterial access site management is a niche but critical component of the interventional cardiology workflow, where procedural volume growth and cost pressure on nursing staff create a persistent need for efficiency gains. Simplicardiac's focus on automating compression and monitoring after transradial catheterization targets a specific point of friction in a high-volume procedure.

Third-party market sizing specific to arterial compression devices is not publicly available in the cited research. However, the broader context is defined by the shift to transradial access (TRA) for coronary procedures, which has become the preferred approach over femoral access due to lower complication rates and faster patient ambulation. A 2021 review in JACC: Cardiovascular Interventions noted TRA adoption exceeded 50% in many European centers and was growing in the US, directly increasing the addressable patient population for post-procedural management devices [JACC: Cardiovascular Interventions, 2021]. The company's own presentation at the TCT Innovation 1 session on "Cath Lab of the Future" in October 2024 positions its solution within this trend toward automation and reduced manual workload [simplicardiac.com].

Demand is driven by two primary forces: clinical efficiency and labor economics. Manual compression and monitoring post-catheterization require dedicated nursing time, creating a bottleneck in high-throughput labs. Any device that demonstrably reduces staff time per patient or enables earlier safe discharge presents a clear value proposition. The second driver is the ongoing push for outpatient or same-day discharge for percutaneous coronary interventions, a trend accelerated by reimbursement models and bed capacity pressures, which increases the need for reliable, automated hemostasis.

Key adjacent markets include the broader vascular closure device (VCD) segment, which is dominated by large-cap medtech players like Abbott and Cardinal Health and focuses primarily on femoral artery closure. These are different products for a different access site, but they represent the established commercial model for selling single-use devices to cath labs. The regulatory pathway in Europe, where Simplicardiac is based, falls under the Medical Device Regulation (MDR), a factor highlighted by the company's active recruitment for a Regulatory Affairs Specialist to act as a Person Responsible for Regulatory Compliance (PRRC) [simplicardiac.com]. Macro forces, including EU funding for industrial property projects like the one Simplicardiac is implementing, can provide non-dilutive capital for patent prosecution and early-stage development [simplicardiac.com].

Partially corroborated -- Market drivers are supported by clinical literature and company positioning; specific TAM/SAM for the niche is not confirmed from independent reports.

Competition and Substitutes

Reported and inferred Simplicardiac enters a specialized hardware segment where competition is defined by long-standing incumbent medical device portfolios and a handful of focused startups.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Simplicardiac	Developer of an automated compression band for transradial arterial access site management.	Seed stage; secured NCBR loan and subsequent investor financing.	Claims a globally unique, patent-pending design for automated monitoring and compression. [simplicardiac.com/technology/, 2026]
Terumo TR Band	Manual radial compression device, a standard of care in many cath labs.	Product of Terumo Corporation, a large public medtech firm.	Ubiquitous market presence and clinical familiarity; a manual, disposable product. [PUBLIC]
Merit Medical PreludeSYNC	Vascular closure device for femoral access, with a radial compression accessory.	Product of Merit Medical, a public medtech firm.	Part of a broader vascular closure portfolio; radial accessory is a secondary offering. [PUBLIC]
SimpleTrials	Provider of clinical trial management software.	Private company; funding not detailed.	Competes for attention and budget in the clinical research ecosystem, not a direct device competitor. [PUBLIC]

The competitive map splits into two distinct layers. The primary competition is at the device level, where large medtech incumbents like Terumo and Merit Medical dominate with manual compression products that are deeply embedded in hospital supply chains and clinician workflows. These are the default, low-cost alternatives against which any new automated system must prove superior clinical and economic value. The secondary layer consists of adjacent solutions, such as SimpleTrials' software, which compete for the same hospital procurement cycles and cardiology department budgets but do not address the physical compression task directly.

Simplicardiac's stated edge rests on its proprietary hardware design, which aims to automate a manual process. The company's pursuit of international patent protection for its "Medical Device for Blood Vessel Compression" is a tangible, if early, step toward creating a defensible technical moat [simplicardiac.com]. This edge is durable only if the patents are granted and are broad enough to block straightforward engineering workarounds. A second, less tangible advantage is the clinical co-founder, Mariusz Kruk, whose role as inventor and professor at the National Institute of Cardiology provides domain credibility for early clinical feedback and study design [LinkedIn, 2026].

The exposure for Simplicardiac is pronounced in commercialization. The company lacks the established sales distribution and regulatory affairs infrastructure of its large-cap competitors. Terumo and Merit Medical have dedicated field teams and decades of experience navigating the FDA and EU MDR pathways for Class II medical devices. Simplicardiac's current hiring for a Regulatory Affairs Specialist underscores this gap as a recognized, active need [simplicardiac.com]. Furthermore, the incumbent products are inexpensive disposables; Simplicardiac's automated system, likely requiring a capital equipment sale or a higher-priced disposable model, faces a steep value-proof hurdle in cost-conscious hospital environments.

The most plausible 18-month scenario hinges on regulatory progress and first commercial reference sites. If Simplicardiac successfully obtains CE marking and places its SimpliRadial devices in a handful of Polish or other European hospitals for a post-market study, it becomes a credible challenger. The "winner" in this case would be Simplicardiac, validating its automated approach. The "loser" would be the broader category of manual-only devices, which would begin to face pressure to innovate. Conversely, if regulatory approval is delayed or the first deployments reveal usability issues, the scenario flips. The winner would be Terumo, whose TR Band would continue its market dominance unchallenged, while Simplicardiac would lose crucial momentum and risk being perceived as a science project rather than a commercial product.

Partially corroborated -- Competitor identification and basic positioning are public; differentiation claims for the subject are from company materials, while incumbent profiles are generalized from public market knowledge.

Opportunity

Open sources If Simplicardiac successfully commercializes its automated arterial-access management device, the prize is a defined role within the high-volume, high-stakes workflow of interventional cardiology, a market where established players command significant value for procedural efficiency and safety.

The headline opportunity is for Simplicardiac to become the standard-of-care device for post-procedural management in transradial catheterization, a method that now represents the majority of coronary interventions globally. This outcome is reachable because the company's product directly addresses a persistent, labor-intensive clinical task with a hardware-based, patent-protected solution. The core concept,automating compression and monitoring,is not an incremental software feature but a tangible device that could be integrated into cath lab protocols. The company's presentation at the TCT Innovation 1 session on the "Cath Lab of the Future" in October 2024 indicates early recognition of the concept's relevance by a major cardiology conference [simplicardiac.com]. The active pursuit of international patent protection for a "Medical Device for Blood Vessel Compression" provides a foundational barrier to entry [simplicardiac.com].

Multiple paths could drive the company from a niche Polish developer to a scaled medtech player. The following scenarios outline concrete, evidence-supported routes to growth.

Scenario	What happens	Catalyst	Why it's plausible
European Standard-Bearer	Simplicardiac's SimpliRadial band becomes the preferred device for transradial procedures in Central and Eastern European hospitals, establishing a regional stronghold.	A successful CE Mark approval and a first major hospital system contract in Poland.	The company is actively hiring a Regulatory Affairs Specialist to handle medical-device market approval, explicitly noting the role may act as the Person Responsible for Regulatory Compliance (PRRC) [simplicardiac.com]. This indicates a focused push for the regulatory milestone required to sell in Europe.
Acquisition by a Global Leader	A large cardiovascular device company (e.g., Terumo, Abbott) acquires Simplicardiac to integrate its automated compression technology into their broader vascular access portfolio.	Clinical data demonstrating superior outcomes in nurse time savings or complication rates compared to existing manual compression bands.	The competitive landscape is dominated by large, acquisitive players like Terumo, which markets the manual TR Band. Simplicardiac's technology represents a logical, automated evolution of that product category, making it a potential tuck-in innovation for a portfolio holder [simplicardiac.com].

Compounding for Simplicardiac would manifest as a clinical data flywheel. Initial deployments in reference hospitals would generate real-world evidence on procedure times, nurse workload, and patient outcomes. This dataset would become a powerful sales and marketing tool, lowering the cost of acquiring subsequent hospital customers by de-risking the adoption decision for clinical directors. The company's current recruitment of a DevOps Engineer suggests an intention to build a digital infrastructure, which could be the foundation for collecting and analyzing this procedural data [simplicardiac.com]. Each new site adds to the evidence base, making the next sale easier and creating a potential data moat around optimal compression protocols.

The size of the win can be framed by looking at comparable transactions and market positions. Terumo Corporation, a leader in vascular access with products like the TR Band, has a market capitalization exceeding $20 billion. While Simplicardiac would not capture that entire value, a successful niche product line within a major medtech can command significant worth. For example, the acquisition of cardiac device startups by larger players often occurs at multiples reflecting the strategic value of patented hardware and clinical traction. If the "Acquisition by a Global Leader" scenario plays out, a credible outcome range could be in the high tens to low hundreds of millions of dollars, depending on clinical validation and commercial pipeline at the time of exit (scenario, not a forecast). This is anchored in the observable market where specialized, patented medtech assets with clear clinical workflows attract premium valuations from strategic buyers seeking innovation.

Partially corroborated -- The opportunity analysis is based on the company's stated product focus and patent activity, its participation in a major industry conference, and its hiring patterns indicating a regulatory push. The acquisition scenario and comparable valuation context are inferred from the competitive landscape and standard medtech M&A dynamics, rather than direct, citable signals of intent.

Sources

Open sources

1. [simplicardiac.com] Simplicardiac | https://simplicardiac.com/

2. [simplicardiac.com/technology/, 2026] Simplicardiac Technology | https://simplicardiac.com/technology/

3. [simplicardiac.com/posts/post03/] Simplicardiac - Posts | https://simplicardiac.com/posts/post03/

4. [simplicardiac.com] Simplicardiac - Careers | https://simplicardiac.com/careers/

5. [Biotechnologia.pl, May 2023] Technologie | https://biotechnologia.pl/technologie?month=5&page=50&year=2023

6. [Onet, May 2020] Brat Szumowskiego: wplątywanie żony ministra jest haniebne | https://wiadomosci.onet.pl/kraj/lukasz-szumowski-i-afera-z-ncbr-brat-komentuje/p02nwek

7. [LinkedIn] Andrzej Białkowski-Miler - Simplicardiac S.A. | LinkedIn | https://www.linkedin.com/in/andrzej-bia%C5%82kowski-miler-84b3b914/

8. [LinkedIn, 2026] Mariusz Kruk | LinkedIn | https://www.linkedin.com/in/mariusz-kruk-...

9. [JACC: Cardiovascular Interventions, 2021] Adoption of Transradial Access for Percutaneous Coronary Intervention | https://www.jacc.org/doi/10.1016/j.jcin.2020.10.013